Liquidia Co. (NASDAQ:LQDA) Receives $24.00 Average Target Price from Brokerages

Shares of Liquidia Co. (NASDAQ:LQDA) have been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $24.00.

Several brokerages have recently weighed in on LQDA. Bank of America cut their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Scotiabank began coverage on shares of Liquidia in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Finally, BTIG Research lowered their price target on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, August 19th.

Liquidia Trading Up 1.7 %

Liquidia stock opened at $11.61 on Friday. The stock has a fifty day moving average price of $10.70 and a 200 day moving average price of $11.37. Liquidia has a 52 week low of $6.82 and a 52 week high of $16.99. The firm has a market capitalization of $982.64 million, a P/E ratio of -7.12 and a beta of 0.21.

Insider Activity

In other news, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the sale, the general counsel now directly owns 486,048 shares in the company, valued at $5,399,993.28. This trade represents a 0.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rajeev Saggar sold 2,526 shares of Liquidia stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $11.19, for a total value of $28,265.94. Following the sale, the insider now directly owns 204,857 shares in the company, valued at approximately $2,292,349.83. The trade was a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,551 shares of company stock worth $236,021. 30.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently bought and sold shares of LQDA. Barclays PLC raised its position in shares of Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock valued at $999,000 after purchasing an additional 72,591 shares in the last quarter. Anson Funds Management LP acquired a new stake in Liquidia in the third quarter valued at $1,764,000. XTX Topco Ltd bought a new position in Liquidia during the 3rd quarter valued at $323,000. Wellington Management Group LLP boosted its stake in Liquidia by 12.5% during the 3rd quarter. Wellington Management Group LLP now owns 179,923 shares of the company’s stock valued at $1,799,000 after acquiring an additional 19,932 shares during the last quarter. Finally, Whitefort Capital Management LP grew its holdings in Liquidia by 119.8% during the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after acquiring an additional 927,546 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).